USA-based Millipore Corp and its UK partner, CXR Biosciences, have launched a new panel of human and rodent cytochrome P450 (CYP450) antibodies for use in drug discovery programs. CXR Biosciences developed the antibodies exclusively for Millipore as a part of a portfolio of innovative discovery toxicology products. CXR says it will also use these new reagents in its own research services business.
CYP450 plays an essential role in drug metabolism in the liver. Understanding drug metabolism is critical in designing more sensitive, and ultimately more predictive, assays for estimating possible liver toxicity, the firms noted, adding that these new antibodies bind to most human isoforms of CYP450, as well as rat and mouse isoforms. The antibodies will be used to develop novel assays for the pharmaceutical, cosmetic, agricultural and industrial sectors. Millipore and CXR claim that their joint offering represents the most comprehensive panel of CYP450 antibodies available for the drug discovery process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze